Antipsychotic Treatment for Chronic Psychotic Symptoms

Initial Treatment Selection

The American College of Psychiatry recommends antipsychotic treatment for individuals with psychotic symptoms and associated distress or functional impairment 1
The choice of initial antipsychotic should be based on efficacy profile and side effect considerations, with risperidone (1.25-3.5 mg/day) recommended as first-line treatment for first-episode psychosis in adults 1
Quetiapine (100-300 mg/day), olanzapine (7.5-15 mg/day), and aripiprazole (15-30 mg/day) are considered high second-line options 1

The treatment guideline suggests beginning with a low dose and gradually titrating up based on response and tolerability, with risperidone started at 1 mg twice daily and increased gradually to the target range of 1.25-3.5 mg/day 1
Allow at least 4 weeks at a therapeutic dose to assess efficacy before considering a medication switch, and document target symptoms and treatment response throughout the titration process 1, 2

Before starting treatment, obtain baseline measurements of BMI, waist circumference, blood pressure, HbA1c, glucose, lipids, prolactin, liver function tests, urea and electrolytes, full blood count, and electrocardiogram 1
Fasting glucose should be rechecked 4 weeks after initiation, and BMI, waist circumference, and blood pressure should be checked weekly for 6 weeks, with all measures repeated after 3 months and annually thereafter 1

If risperidone is ineffective or poorly tolerated after 4 weeks at a therapeutic dose, consider switching to an alternative antipsychotic with a different pharmacodynamic profile, such as quetiapine (100-300 mg/day), olanzapine (7.5-15 mg/day), or aripiprazole (15-30 mg/day) 1
If two adequate antipsychotic trials fail, clozapine should be considered, according to the treatment guidelines 1, 3

Risperidone has a lower risk of metabolic side effects compared to olanzapine but may cause hyperprolactinemia, while olanzapine carries a higher risk of weight gain and metabolic disturbances 1, 4

For chronic psychotic symptoms, long-term treatment is typically required, with the need for continued treatment reassessed periodically, and the lowest effective dose used to minimize side effects while maintaining symptom control 2
Abrupt discontinuation should be avoided due to the risk of symptom recurrence 5

For patients with comorbid conditions like diabetes or obesity, avoid olanzapine and clozapine as first-line options, and consider potential drug interactions if the patient is on other medications 3
Adherence is critical for treatment success, and long-acting injectable formulations may be considered if adherence becomes an issue 3, 6